Prime Medicine (NYSE:PRME – Get Free Report) and CEL-SCI (NYSE:CVM – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Prime Medicine and CEL-SCI, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 3 | 4 | 1 | 2.75 |
| CEL-SCI | 0 | 0 | 0 | 0 | 0.00 |
Prime Medicine presently has a consensus price target of $8.92, suggesting a potential upside of 119.08%. Given Prime Medicine’s stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than CEL-SCI.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | $4.96 million | 110.40 | -$198.13 million | ($1.56) | -2.61 |
| CEL-SCI | N/A | N/A | -$26.92 million | ($9.77) | -1.05 |
CEL-SCI has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Prime Medicine and CEL-SCI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| CEL-SCI | N/A | -238.05% | -104.65% |
Risk and Volatility
Prime Medicine has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Insider & Institutional Ownership
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Comparatively, 14.1% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Prime Medicine beats CEL-SCI on 12 of the 13 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
